ICLR

Wawanesa Insurance Announces Wildfire Prevention Grant Recipients

Retrieved on: 
Tuesday, April 9, 2024
Partnership, Wildfire, Resilience, Wilderness, Fire, Township, ICLR, Douro-Dummer, Wawanesa

WINNIPEG, Manitoba, April 09, 2024 (GLOBE NEWSWIRE) -- The Wawanesa Mutual Insurance Company (Wawanesa) today announced the 12 recipients of their second annual Community Wildfire Prevention Grants, which were developed in partnership with FireSmartTM Canada and the Institute for Catastrophic Loss Reduction (ICLR).

Key Points: 
  • WINNIPEG, Manitoba, April 09, 2024 (GLOBE NEWSWIRE) -- The Wawanesa Mutual Insurance Company (Wawanesa) today announced the 12 recipients of their second annual Community Wildfire Prevention Grants, which were developed in partnership with FireSmartTM Canada and the Institute for Catastrophic Loss Reduction (ICLR).
  • “Supporting community wildfire prevention helps build a safer, more sustainable future for us all,” said Anna McCrindell, Wawanesa’s SVP & Chief Operating Officer, East.
  • The grants will go toward a range of wildfire prevention activities, such as creating wildfire buffer zones around homes, home assessments with sprinkler kit incentives, public education, community wildfire protection plans, and more.
  • Wawanesa’s Community Wildfire Prevention Grants Program reinforces the key message that more wildfires don’t have to translate into more loss of communities.

ICON Announces CFO Transition

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Medical Devices, Health, Finance, Pharmaceutical, Biotechnology, ICON PLC, Pleasure, ICLR, PRA Health Sciences, Growth, CFO, Management

Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer.

Key Points: 
  • Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer.
  • ICON has commenced a search to identify the next CFO.
  • “On behalf of the ICON Board and Leadership Team, I want to thank Brendan for his strong contributions to ICON over his 18 years, including 12 years as CFO,” said Steve Cutler, ICON’s CEO.
  • We have commenced a search to identify our next CFO and will update on that process at the appropriate time.

ICON plc Schedules First Quarter 2024 Earnings Conference Call

Retrieved on: 
Monday, March 25, 2024
Professional Services, Health, Other Professional Services, Finance, Clinical Trials, Pharmaceutical, Biotechnology, ICLR, ICON PLC

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, April 24, 2024.

Key Points: 
  • ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, April 24, 2024.
  • The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 25, 2024 at 8:00am ET.
  • Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “ Events ”.
  • A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

ICON plc to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 26, 2024
Research, Medical Devices, Finance, Clinical Trials, Health Technology, Professional Services, Biotechnology, Pharmaceutical, Health, Science, CFO, ICLR, Barclays, ICON PLC, Conference

ICON plc , (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 2:05 pm ET.

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 2:05 pm ET.

 ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call

Retrieved on: 
Tuesday, January 30, 2024
Other Health, Research, Professional Services, Pharmaceutical, Medical Devices, Health Technology, Clinical Trials, Science, Biotechnology, Finance, Other Science, Health, ICON PLC, ICLR

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the fourth quarter and full year 2023 results after the market closes on Wednesday, February 21, 2024.

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the fourth quarter and full year 2023 results after the market closes on Wednesday, February 21, 2024.
  • The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 22, 2024 at 8:00am ET.
  • Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “ Events ”.
  • A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment

Retrieved on: 
Wednesday, January 24, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Fitness & Nutrition, Clinical Trials, Obesity, Patient, GIP, Therapy, MASH, Internal medicine, Hormone, ICON PLC, ICLR, Disease, Safety, Drug development, Liver disease, Steatosis, Clinical trial, Metabolism, Cardiovascular disease, Bariatric surgery, Pharmaceutical industry

The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome.

Key Points: 
  • The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome.
  • There is much overlap between obesity and co-morbidities such as diabetes, steatosis (fatty liver), and cardiovascular disease, and in line with this, most respondents (64%) felt combination therapies would be the primary focus of future research.
  • Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year because of the disease1.
  • There is more to examine on the implications of obesity as a risk factor across the disease spectrum and how it may impact treatment, drug development and clinical trials for obesity.

ICON Issues Financial Guidance for Full Year 2024

Retrieved on: 
Tuesday, January 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Clinical Trials, ICLR, GAAP, Share repurchase, Investment, Automation, Patient, ICON PLC, Public expenditure, Growth, Pharmaceutical industry

ICON plc , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2024.

Key Points: 
  • ICON plc , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2024.
  • We remain focused on driving efficiency in clinical trials through investments in automation, innovative tools and initiatives to increase participation for sites and patients in clinical research.
  • 1 The full-year 2023 and 2024 guidance adjusted earnings per share measures are provided on a non-GAAP basis because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts.
  • For the same reasons, the company is unable to address the probable significance of the unavailable information.

Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON

Retrieved on: 
Monday, January 8, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Incubator, ICLR, ChromeOS, ICON PLC, Communication, Pharmaceutical industry

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper.

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper.
  • A recent survey of over 130 biotech executives, published by ICON, shows that 60% of respondents expected to increase R&D spending, whilst only 2% planned to reduce funding.
  • This finding suggests an opportunity for biotechs to consider how they can work more comprehensively with their clinical development partners.
  • Chris Smyth, President of ICON Biotech, commented: “Biotech companies’ lean structural models mean they outsource a large proportion of their clinical development and R&D activity.

ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Research, Medical Devices, Finance, Health Technology, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Conference, ICLR, ICON PLC

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:15pm PST/8.15pm EST.

Key Points: 

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:15pm PST/8.15pm EST.

ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023

Retrieved on: 
Monday, December 18, 2023
Research, Technology, Clinical Trials, Professional Services, Biotechnology, Pharmaceutical, Health, Environmental, Social and Governance (ESG), Science, Artificial Intelligence, Social, Woman, European Medicines Agency, Clinical trial, Industry Dive, Gold, KPI-driven code analysis, EMA, ICLR, Platinum, AG, FDA, ICON PLC, Biophysical environment, IDEA, Frost, Growth, Workplace, Environment, Graphics, ESG, Fine chemical, Pharmaceutical industry, ICON

ICON was also included on both the Forbes World’s Best Employers and World’s Top Companies for Women lists for 2023 and was the only CRO to feature in the ‘Drugs and Biotechnology’ industry sector for both awards.

Key Points: 
  • ICON was also included on both the Forbes World’s Best Employers and World’s Top Companies for Women lists for 2023 and was the only CRO to feature in the ‘Drugs and Biotechnology’ industry sector for both awards.
  • For the second year running, ICON received the Financial Times Leaders in Diversity Award.
  • Steve Cutler, CEO, ICON noted: “ICON works hard to build an environment that nurtures growth and success for all.
  • Furthermore, at the 2023 Rx Club Show Awards, ICON was an award winner in the print, interactive and video category.